Press Releases

Show events starting after a certain date ( i.e. YYYY-MM-DD)
Show events starting before a certain date ( i.e. YYYY-MM-DD)
There are currently no events to display.
Jun 20 2017
Summary ToggleAdverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer  
May 22 2017
Summary ToggleAdverum Biotechnologies to Present at the Jefferies Global Healthcare Conference  
May 10 2017
Summary ToggleAdverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings  
May 9 2017
Summary ToggleAdverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update  
Apr 20 2017
Summary ToggleAdverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors  
Apr 17 2017
Summary ToggleAdverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day  
Apr 6 2017
Summary ToggleAdverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day  
Mar 14 2017
Summary ToggleAdverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors  
Mar 6 2017
Summary ToggleAdverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update  
Feb 21 2017
Summary ToggleAdverum Biotechnologies to Present at Upcoming Investor Conferences  
Jan 18 2017
Summary ToggleAdverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017  
Nov 9 2016
Summary ToggleAdverum Biotechnologies to Present at Upcoming Investor Conferences  
Nov 8 2016
Summary ToggleAdverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results  
Oct 20 2016
Summary ToggleAdverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) Meeting  
Oct 14 2016
Summary ToggleAdverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program  
Oct 14 2016
Summary ToggleAdverum Biotechnologies, Inc. Announces New Executive Chair and CEO  
Oct 13 2016
Summary ToggleAdverum Biotechnologies to Present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting  
Sep 16 2016
Summary ToggleAdverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting  
Aug 9 2016
Summary ToggleAdverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results  
Aug 9 2016
Summary ToggleAdverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye  
Jul 7 2016
Summary ToggleAdverum Biotechnologies Provides wet AMD Program Update  
Jun 13 2016
Summary ToggleAdverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer  
May 12 2016
Summary ToggleAvalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies  
May 10 2016
Summary ToggleAvalanche Biotechnologies’ Stockholders Vote in Favor of Annapurna Transaction  
May 6 2016
Summary ToggleAvalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results  
Apr 27 2016
Summary ToggleAvalanche Biotechnologies to Present at Upcoming Scientific Meetings  
Mar 3 2016
Summary ToggleAvalanche Biotechnologies Reports Fourth Quarter and Fiscal 2015 Financial Results  
Mar 2 2016
Summary ToggleAvalanche Biotechnologies to Present at Upcoming Investor Conferences  
Feb 1 2016
Summary ToggleAvalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger  
Nov 20 2015
Summary ToggleAvalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO  
Nov 9 2015
Summary ToggleAvalanche Biotechnologies, Inc. Reports Third Quarter 2015 Financial Results  
Aug 13 2015
Summary ToggleAvalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program  
Aug 5 2015
Summary ToggleAvalanche Biotechnologies Awarded as Technology Pioneer by World Economic Forum  
Jul 23 2015
Summary ToggleAvalanche Biotechnologies Announces Leadership Transition  
Jun 15 2015
Summary ToggleAvalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration  
May 14 2015
Summary ToggleAvalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting  
May 13 2015
Summary ToggleAvalanche Biotechnologies, Inc. Reports First Quarter 2015 Financial Results  
Apr 28 2015
Summary ToggleAvalanche Biotechnologies to Present at Upcoming Scientific Meetings  
Mar 25 2015
Summary ToggleAvalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness  
Mar 18 2015
Summary ToggleAvalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015  
Mar 5 2015
Summary ToggleAvalanche Biotechnologies, Inc. Reports Fourth Quarter and Fiscal 2014 Financial Results  
Feb 25 2015
Summary ToggleAvalanche Biotechnologies to Present at Upcoming Investor Conferences  
Jan 8 2015
Summary ToggleAvalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock  
Jan 5 2015
Summary ToggleAvalanche Biotechnologies Announces Proposed Public Offering of Common Stock and Partial Release of Lock-Up Agreements in Connection Therewith  
Nov 26 2014
Summary ToggleAvalanche Biotechnologies to Present at the 26th Annual Piper Jaffray Healthcare Conference  
Nov 13 2014
Summary ToggleAvalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference  
Nov 12 2014
Summary ToggleAvalanche Biotechnologies, Inc. Reports Third Quarter 2014 Financial Results  
Oct 30 2014
Summary ToggleAvalanche Biotechnologies to Participate in Nomura's Biotechnology Conference  
Oct 9 2014
Summary ToggleAvalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting  
Oct 1 2014
Summary ToggleAvalanche Biotechnologies to Participate in Gene Therapy Panel at the BIO Investor Forum  
Sep 23 2014
Summary ToggleAvalanche Biotechnologies, Inc., Appoints Industry Leader Roman G. Rubio, M.D., as Senior Vice President and Head of Translational Medicine  
Sep 19 2014
Summary ToggleAvalanche Biotechnologies to Present at the NewsMakers in the Biotech Industry Conference  
Sep 11 2014
Summary ToggleAvalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results  
Aug 5 2014
Summary ToggleAvalanche Biotechnologies Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares  
Jul 31 2014
Summary ToggleAvalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock  
Jul 1 2014
Summary ToggleAvalanche Biotechnologies Announces Appointment of Samuel B. Barone, M.D., as Chief Medical Officer  
May 20 2014
Summary ToggleAvalanche Biotechnologies Announces Appointment of Industry Veteran Linda C. Bain as Chief Financial Officer  
May 5 2014
Summary ToggleRegeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology  
Apr 22 2014
Summary ToggleAvalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing  
Nov 22 2013
Summary ToggleAvalanche Raises Additional Funding in Follow-On Financing  
Jun 12 2013
Summary ToggleAvalanche’s Novel Technology Restores Vision in Pre-Clinical Models of Blindness  
Oct 1 2012
Summary ToggleAvalanche Biotechnologies, Inc. Announced That it Has Been Awarded Two Grants from the National Eye Institute to Fund Pre-clinical Studies Related to its Novel AAV Variant Technology  
May 16 2012
Summary ToggleAvalanche Biotechnologies, Inc. and Lonza Announce Global Manufacturing Collaboration for Adeno-associated Viral Vectors for Gene Therapy  
Nov 1 2011
Summary ToggleAvalanche Announces Collaboration with Lions Eye Institute and Merck to Develop AVA-101